In prostate cancer, p300 acetylation could either prevent AR binding directly by β-catenin, as suggested by Levy et al. [28], or it could alternatively affect FKBP52 binding to β-catenin, thereby favoring the binding of TCF4 over AR. This evidence concerns the gene TCF4 and prostate carcinoma.